NADPH reductase Inhibitors
2 drugsAbout NADPH reductase
NADPH reductase is an enzyme essential for cellular redox balance, catalyzing the reduction of NADP+ to NADPH. This reaction provides a critical reducing agent used in anabolic reactions and antioxidant defense, impacting various metabolic pathways.
Currently, there is no genetic evidence directly linking NADPH reductase to specific diseases. However, the existence of two FDA-approved drugs targeting this enzyme demonstrates its potential as a therapeutic target.
Two FDA-approved small molecule drugs, METHYLENE BLUE and PROVAYBLUE, target NADPH reductase. These drugs, developed by ZYDUS LIFESCIENCES and PROVEPHARM SAS respectively, highlight the feasibility of modulating NADPH reductase activity.
Top NADPH reductase Drugs
The competitive landscape includes two companies, ZYDUS LIFESCIENCES and PROVEPHARM SAS, with approved drugs.
Low market concentration suggests opportunities for new entrants, but also highlights potential challenges in establishing market share.
NADPH reductase Drug Modality Landscape
Modalities
Routes of Administration
NADPH reductase is druggable by small molecules, though no oral formulations are currently approved.
Explore alternative modalities like biologics to differentiate from existing therapies and expand market potential.
NADPH reductase Clinical Trials 47 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on NADPH reductase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 5 | 0 | 3 | 100% |
| Phase 2 | 24 | 16 | 2 | 6 | 89% |
| Phase 3 | 7 | 4 | 0 | 3 | 100% |
| Phase 4 | 8 | 4 | 1 | 3 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
NADPH reductase Drug Approval Timeline (2016 - 2023)
The first drug was approved in 2016, with the most recent approval in 2023, spanning 8 years.
Recent approval suggests renewed interest, but further approvals are needed to confirm sustained therapeutic relevance.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 38 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on NADPH reductase. A trial counts if an approved drug acting on NADPH reductase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.